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Introduction
The incidence of lung cancer in the United States has
been steadily increasing in recent years, and lung can-
cer now ranks as the primary cause of death from can-
cer in American men [1]. Non-small cell carcinomas
account for about 85% of all lung cancers. About 60%
of lung cancers are adenocarcinomas, and about 26%
are squamous cell carcinomas [2]. The proportion of
adenocarcinomas has been increasing recently, and the
percentage of woman with adenocarcinoma has also
been rising [3]. 
Adenocarcinomas are the most common epithelial
malignancies found in body cavity fluids. Common
primary sites include the lung, breast, gastrointestinal
tract, and genitourinary tract. Identification of the spe-
cific site of origin may carry important prognostic as
well as therapeutic implications. However, determina-
tion of the primary site of adenocarcinoma based on
cytomorphology alone can be a challenging task. Tis-
sue specific immunohistochemical markers offer an
attractive means for confirming metastatic disease in
patients with known primary tumors and may assist in
identifying the primary sites in patients with adenocar-
cinomas of unknown origin.
Blobel et al. [4] showed that alveolar cells of
human lung contained cytokeratin (CK) polypeptides
typical of simple epithelia (CK7, 8, 18, and 19). Basal
cells of the bronchial epithelium, on the other hand,
contained CK5 and small amounts of CK6. Conse-
quently, it has been also found "simple-epithelium-
type" cytokeratins in all adenocarcinomas and later
also in squamous cell carcinomas [5]. CK8 is the most
widely expressed cytokeratin in various epithelial cells
and cancer cells among at least 21 related cytokeratins
[6]. One study has demonstrated that CK8 is found in
the serum of a subgroup of patients with non-small cell
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lung carcinomas [7]. CK7, a neutral-basic type II
cytokeratin found in adenocarcinomas of breast and
lung, among others [8-10].
Alkaline phosphatase (AP) isoenzymes are widely
distributed in various organs, and activity and/or AP
identification in bronchial fluid is a marker of lung car-
cinoma and metastases [11-13]. Human APs are
reportedly encoded by four different genes: a gene fort
he liver/bone/kidney isozyme (tissue-nonspecific type,
TNAP), a gene for the adult intestinal isozyme (IAP) 
a gene for the placental (PLAP), a gene for the germ
cell isozyme (placental-like AP or GCAP [14]. TNAP
is the predominant AP isozyme in the lung, where it is
largely produced by type II pneumocytes [15], but
trace amounts of PLAP are also expressed by type I
pneumocytes [16].
Muensh et al. [17] have found that AP is elevated in
23% of 286 patients suffering from various neoplasms.
AP was elevated most commonly in cases of colorec-
tal cancer (54%), ovarian cancer (44%) and lung can-
cer (40%). It seems that expression of certain cytoker-
atins (CK7, CK8) and AP may be useful in the diagno-
sis of primary lung adenocarcinomas. This study was
undertaken to evaluate the clinical utility of CK7, CK8
and AP in the diagnosis of primary lung adenocarcino-
ma in body cavity fluids specimens. 
Materials and methods
Cases. The cytological files of the Hannover Cytopathology
Institute were reviewed between 6 January 2005 and 21 February
2007. The 148 pleural fluids were collected from 148 patients
who were diagnosed with adenocarcinoma. Medical records were
reviewed to verify that the cases were of primary lung origin and
did not represent metastatic disease from primary tumors at other
sites. The selection of patients was restricted to include those in
whom the primary site of origin for the carcinoma was confirmed
based on clinical findings (n=148). Slides that were stained pre-
viously by routine Giemsa methods were retrieved for each
patient. The diagnosis of adenocarcinoma based on cytomorphol-
ogy was confirmed. Classic cytologic features of malignancy
included three-dimensional aggregates comprised of cells with
increased nuclear-to-cytoplasmic ratios, irregular nuclear mem-
branes, course chromatin, large irregular nucleoli and finely vac-
uolated cytoplasm. The sensitivity of CK7, CK8 and AP in body
cavity fluid samples for primary lung adenocarcinomas were cal-
culated.
Immunocytochemistry procedure. Cytological smears were pre-
pared by standard cytologic method. The slides were hydrated in
decreasing ethanol solutions. Endogenous peroxidase was blocked
with hydrogen peroxidase for 3 minutes. The slides were rinsed in
water, were incubated with the biotin blocking system (Dako) prior
to application of the primary antibody. The CK7 and CK8 mono-
clonal antibodies were used at a dilution of 1:100 and incubated
with the samples for 1 hour. The slides were then rinsed in buffer
and incubated for 25 minutes with the linking solution (LSAB+ kit;
Dako; biotinylated antimouse, antirabbit, and antigoat). This was
followed by a rinse in buffer and incubation with streptavidin per-
oksidase for 25 minutes. After rinsing in buffer, the slides were
submerged in AEC for 5 minutes. The slides were counterstined
with Mayer's hematoxilen. The slides were then dehydrated
through gradient alcohols, cleared in xylene, and coverslipped.
Only cytoplasmic staining was regarded as a positive result. The
intensity of staining was graded on a 0 (absent),1+ (weak), 2+
(moderate), and 3+ (strong). All material was evaluated blindly by
two observers. Statistical analysis was performed using the chi-
squared test and the orthagonal test. The chi-square test was used
to determine statistical significance.
Enzyme cytochemistry. For detection of AP activity, 17.5 mg nap-
tithyle phosphate sodium salt monohydrate were dissolved in 
35 ml o.1 mole veronalnatrium buffer (pH=9.4) and mixed with 
35 mg variamine blue B salt. The mixture was freshly prepared
before use. We incubated cells for 60 minutes at 4°C and counter-
stained with Mayer's hemalum solution for 4 min. Then the slides
were mounted with glycerol gelatin. Cytoplasmic staining of tumor
cell was considered positive.
Results 
The results of AP, CK7, CK8 immunostaining of lung
adenocarcinomas in 148 pleura fluids are shown in
Table 1. AP was expressed in 81% of primary lung
adenocarcinomas. Positive immunoreactivity for AP
was characterized by a red diffusely cytoplasmic
staining in tumor cells that ocurred singly or in
groups. AP showed cytoplasmic staining in adenocar-
cinoma cells (Fig. 1). 27 of 148 fluids from adeno-
carcinoma of lung origin were negative for AP. 95
(65%) primary lung carcinoma samples were positive
for CK7 (Fig.2a, b). 
Overall results for primary lung adenocarcinomas
demonstrated CK8 reactivity in 106 (72%) of 148
cases (Fig.3). Staining intensity was moderate in most
primary (1+, 31 cases; 2+, 52 cases; 3+, 23 cases) lung
adenocarcinomas. 
Table 1 has showed the staining patterns of primary
lung adenocarcinomas from pleural effusions for AP,
CK7 and CK8. For all primary lung adenocarcinomas
studied, 121 (81%) of cases exhibited AP, 95 (65%) of
cases exhibited CK7, 106 (72%) of cases exhibited
CK8 immunostaining.
There was a significant difference between AP,
CK7 and CK8 expressions in primary lung adenocar-
cinomas (P=0.02; Chi-squared test). The statistical
values are given in Table 2. The sensitivity of AP, CK7
and CK8 as a marker for primary lung adenocarcino-
ma were 82%, 64%, and 72% respectively. AP had the
highest sensitivity of the primary lung adenocarcino-
ma studied, with a sensitivity of 82%.
Discussion
Adenocarcinoma is the most common cause of malig-
nancy in body cavity fluids. Usual primary sites include
the lung, breast, gastrointestinal tract, and genitouri-
nary tracts. Predicting the site of origin of an
adenocarcinoma can be difficult due to overlapping
morphologic characteristics. Lung is a common primary
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site for adenocarcinomas in body cavity fluids [18-20].
We investigated the use of AP, CK7 CK8 to distinguish
adenocarcinomas of lung in 148 pleura fluids. 
Organ specific markers using immunohistochem-
istry offer an attractive means for subclassifying ade-
nocarcinomas according to primary site. CK7 and CK8
are tissue specific protein expressed selectively in the
epithelial cells of the lung [21].
Cytokeratins, belonging to the intermediate fila-
ment (IF) protein family, are particularly useful tools
in oncology diagnostics. At present, more than 20 dif-
ferent cytokeratins have been identified, of which
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Table 1. Staining intensity of AP, CK7 and CK8 in primary lung adenocarcinomas from pleural effusions.
Figure 1. Cytochemical staining of
primary lung adenocarcinoma with
alkaline phosphatase. Couterstained
with hematoxylin (pleura, original
magnification x 600)
Figures 2a,b. Two primary lung adenocarcinoma samples show intense cytoplasmic staining with cytokeratin 7 ((a) Pleura, immunoper-
oxidase-hematoxylin, x200) and (b) Pleura, immunoperoxidase-hematoxylin, x400)
cytokeratins 8, 18, and 19 are the most abundant in
simple epithelial cells. Upon release from proliferating
or apoptotic cells, cytokeratins provide useful markers
for epithelial malignancies. Previous examination has
demonstrated CK 7 and CK 8 positivity in the vast
majority of lung adenocarcinomas studied [7,22].
Using commercially available monoclonal antibody
for CK8, we demonstrated a sensitivity of 72% for
lung adenocarcinomas. 95 primary lung carcinoma
samples (65%) were positive for CK7. The sensitivity
of CK7 as a marker for primary lung adenocarcinomas
was 65%. 
Human alkaline phosphatase isoenzymes have been
classified electrophoretically and immunohistochemi-
cally into four major groups: hepatic, intestinal, bone
and placental [23]. Placental alkaline phosphatase
(PLAP) levels are elevated during pregnancy and in
cigarette smokers. However, in non-pregnant women
and non-smokers, PLAP activity is very low, compro-
mising less than 1% of the total alkaline phosphatase
activity [17,24].
Following the discovery by Fishman et al. [14] that
PLAP elevation is associated with bronchogenic carci-
noma, many other studies have confirmed that this
isoenzyme is ectopically produced by various neo-
plasms [25-27]. Muensh et al. [17] have found, that
PLAP is elevated in 23% of 286 patients suffering
from various neoplasms. PLAP was elevated most
commonly in cases of colorectal cancer (54%), ovari-
an cancer (44%) and lung cancer (40%). Other studies
have confirmed raised serum concentrations of this
alkaline phosphatase isoenzyme in 15-64% of patients
with ovarian cancer [28-31]. One study showed that
almost all ovarian cancer tissues contained PLAP to
some extend, however there was a low frequency of
detectable serum levels of PLAP, especially in the
early stages of the disease [29]. In this study, AP was
expressed in 81% of primary lung adenocarcinomas.
Positive immunoreactivity for AP was characterized
by a red diffusely cytoplasmic staining in tumor cells
that ocurred singly or in groups. The specificity and
positive predictive values of the AP antibody for the
adenocarcinomas of lung origin in our series were both
81%.
Staining for AP activity is a rapid and simple test,
which does not require any special equipment. When
used carefully and in conjunction with additional test-
ing such as cytology, detection of AP activity appears
to be a useful tool in the diagnosis of primary lung ade-
nocarcinom. Generally, the cytologic and clinical fea-
tures of the tumors can assist in diagnosis. In addition,
detection of AP activity only improves the ability of
the clinician and pathologist to appropriately diagnose
primary adenocarcinoma of lung.
This application of the AP marker onto cytological
slides of lung adenocarcinoma can be very helpful in
daily clinical cytology practice. The staining technique
is simple, and the AP yields highly sensitive results. 
A positive reaction for AP may serve to confirm the
spread of a known primary lung tumor, establish the
recurrence of a previously treated adenocarcinoma of
the lung, or identify the lung as a possible source of
malignancy in a patient with an unknown primary site.
In this study, AP was expressed in 81% of primary
lung adenocarcinomas. Positive immunoreactivity for
AP was characterized by a red diffusely cytoplasmic
staining in tumor cells that ocurred singly or in groups.
The specificity and positive predictive values of the
AP antibody for the adenocarcinomas of lung origin in
our series were both 81%. 27 of 148 fluids from ade-
nocarcinoma of lung origin were negative for AP. 
The histologic distinction between primary pul-
monary adenocarcinomas and adenocarcinomas
metastases to the lung can be a difficult task, with sig-
nificant clinical ramifications. In this regard, immuno-
histochemical evaluation of CK7 and CK8 and AP
expression patterns has been a useful method of accu-
rately classifying these entities [32-36].
Our findings have confirmed the results of other
studies with regard to the high frequency and intensity
of CK7, CK8 and AP expressions in lung adenocarci-
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Table 2. Sensitivity values of AP, CK7 and CK8 staining in pri-
mary lung adenocarcinomas.
Figure 3. Immunocytochemical staining for cytokeratin 8 in 
a group of lung adenocarcinoma cells (Pleura, immunoperoxidase-
hematoxylin, x400)
nomas [37-40]. The sensitivity of AP, CK8, CK7 as 
a marker for primary lung adenocarcinomas were
81%, 72%, 65%, respectively. Thus the AP positive
staining largely confirmed the cytologic diagnosis of
lung adenocarcinoma.
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